SEARCH OUR PRODUCT CATALOG

CANCER PATIENT SELECTION FOR ADMINISTRATION OF WNT SIGNALING INHIBITORS USING RNF43 MUTATION STATUS

2017-10-27 14:13:11

CZECH MYCOLOGY 69(2): 143–162, NOVEMBER 10, 2017 (ONLINE VERSION, ISSN 1805-1421)

POHNERT, STEVEN C



Abstract


Disclosed are biomarkers, methods and assay for the identification of cancer patients who are predicted to benefit from the therapeutic administration of Wnt antagonist. The biomarkers include detection of RNF43 and ZNRF3 gene deletion, reduced RNF43 and ZNRF3 mRNA expression, reduced RNF43 and ZNRF3 protein expression, RNF43 and ZNRF3 inactivation mutation, phosphorylated LRP6, phophorylated Dishevelleds, and the expression of Frizzleds. These biomarkers can be associated with the better outcome for cancer patients treated with Wnt pathway inhibitors.





Empire Genomic's ZNRF3 and RNF43 FISH Probes were used in this publication.



To Access Article, Click Here